PLx Pharma (FRA:1D5A) Debt-to-Equity : 0.00 (As of Sep. 2022)

View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma Debt-to-Equity?

PLx Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was €0.00 Mil. PLx Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was €0.00 Mil. PLx Pharma's Total Stockholders Equity for the quarter that ended in Sep. 2022 was €26.46 Mil. PLx Pharma's debt to equity for the quarter that ended in Sep. 2022 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for PLx Pharma's Debt-to-Equity or its related term are showing as below:

FRA:1D5A's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.29
* Ranked among companies with meaningful Debt-to-Equity only.

PLx Pharma Debt-to-Equity Historical Data

The historical data trend for PLx Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PLx Pharma Debt-to-Equity Chart

PLx Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Debt-to-Equity

Get a 7-Day Free Trial

1.50

1.12

2.73

0.06

PLx Pharma Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of PLx Pharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, PLx Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PLx Pharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PLx Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where PLx Pharma's Debt-to-Equity falls into.

PLx Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

PLx Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	45.737
	=	0.00

PLx Pharma's Debt to Equity Ratio for the quarter that ended in Sep. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	26.463
	=	0.00

PLx Pharma (FRA:1D5A) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

PLx Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of PLx Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

PLx Pharma (FRA:1D5A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Inc (FRA:1D5A) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 The Green, Suite 11895, Dover, DE, USA, 19901

Website

https://www.plxpharma.com

PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.

PLx Pharma (FRA:1D5A) Headlines

No Headlines